NCT02224066

Platelet Reactivity After TAVI: A Multicenter Pilot Study

Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: Hospital de Meixoeiro · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A high platelet reactivity in patients with severe symptomatic Aortic Stenosis (AS) selected for TAVI (Transcatheter aortic valve implantation) procedure has been demonstrated previously, and the use of double antiaggregation therapy (DAPT) with Clopidogrel and Acetylsalicylic acid (ASA) do not achieve consistent and adequate suppression of platelet reactivity. The purpose of this study is evaluate the efficacy of ticagrelor alone versus DAPT with clopidogrel and aspirin for the suppression of high platelet reactivity following TAVI.

Conditions

• Severe Aortic Valve Stenosis
• Transcatheter Aortic Valve Implantation
• Transcatheter Aortic Valve Replacement

Interventions

Type	Name	Description
DRUG	Ticagrelor 90 mg twice per day during three months following TAVI
DRUG	Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI

Timeline

• Start date: 2016-01-01
• Primary completion: 2017-05-01
• Completion: 2018-08-01
• First posted: 2014-08-25
• Last updated: 2018-08-03

Locations

7 sites across 1 country: Spain